Director Yao Hong and his delegation from the Tumor Biotherapy Center of Yunnan Cancer Hospital visited Shenzhen Cell Valley
Under the detailed introduction of Chairman Professor Shi Yuanyuan, the visiting leaders visited the digital intelligence exhibition hall of Shenzhen Cell Valley, and discussed the strategic deployment and domestic and international strategic layout of Cell Valley; Core technological advantages, GMP level industrial preparation of virus vectors and cell products; And we have gained a deeper understanding of future development trends. Subsequently, I delved into research and development, production, and quality management laboratories, gaining a more intuitive understanding of the actual operational processes and quality management system.
At the symposium, Professor Shi Yuanyuan introduced that Shenzhen Cell Valley has a leading position in domestic retroviral vector technology (PackRV SS and other systems), and retroviral vectors have safety advantages and cost advantages for industrial production. At the same time, Shenzhen Cell Valley has developed and industrialized the BaEV enveloped retroviral packaging engineering cell line with independent intellectual property rights, and the positive rate of transduced T cells and NK cells exceeds 90%, and the positive rate has not decreased. Shenzhen Cell Valley has continuously researched and developed technology, from the preparation of spot cell products to the quality control of storage and recovery, and has established a clinical grade CAR product library. Shenzhen Cell Valley has established substantial and comprehensive cooperation with multiple hospitals, leveraging its strong advantages in core technology, production system, quality control system, and talent team. It has accumulated many successful experiences in co building cell preparation centers and jointly applying for clinical research projects.
Director Yao Hong recognized the core technology and clinical application cases mastered by Shenzhen Cell Valley, and introduced that Yunnan Cancer Hospital is a tertiary Grade A specialized hospital in Yunnan Province that integrates medical treatment, teaching, scientific research, and prevention. In 2021, it was approved as a national cancer regional medical center construction project, undertaking the tasks of tumor prevention and treatment research, talent cultivation, and tumor academic exchange in the region. At the same time, as a directly affiliated hospital of Kunming Medical University, it has 10 teaching and research rooms, 33 doctoral supervisors, and 197 master's supervisors, forming a talent cultivation system for undergraduate, master's, doctoral, continuing medical education, and international student training. The purpose of this exchange is to understand the current development status of cell and gene therapy through Shenzhen Cell Valley, and to explore cooperation in the field of cell therapy at Yunnan Cancer Hospital.
This exchange has enhanced mutual understanding, and both parties hope to carry out broader cooperation in the future, deepen cooperation in building a cell preparation center, jointly apply for clinical research projects, enhance talent cultivation and exchange, and help promote the development of the cell and gene industry.
